AIMS: National studies have demonstrated disparities in the treatment and survival of pancreatic cancer patients based on socioeconomic status (SES). This study aimed to identify specific differences in perioperative management and outcomes based on patient SES and to study the role of a multidisciplinary clinic (MDC) in mitigating any variations. METHODS: The study analyzed patients undergoing pancreaticoduodenectomy for pancreatic ductal adenocarcinoma in a large hospital system. The patients were categorized into groups of high and low SES and whether they were managed by the authors' pancreatic cancer MDC or not. The study compared differences in disease characteristics, receipt of multimodality therapy, perioperative outcomes, and recurrence-free and overall survival. RESULTS: Of the 162 low-SES patients and 119 high-SES patients, 54% were managed in the MDC. Outside the MDC, low-SES patients were less likely to receive neoadjuvant chemotherapy and had less minimally invasive surgery, a longer OR time, less enhanced recovery participation, and more major complications (p < 0.05). No SES disparities were observed among the MDC patients. Despite similar tumor characteristics, the low-SES patients had inferior median overall survival (21 vs 32 months; p = 0.005), but the MDC appeared to eliminate this disparity. Low SES correlated with inferior survival for the non-MDC patients (17 vs 32 months; p < 0.001), but not for the MDC patients (24 vs 25 months; p = 0.33). These findings persisted in the multivariable analysis. CONCLUSION: A pancreatic cancer MDC standardizes treatment decisions, eliminates disparities in surgical outcomes, and improves survival for low-SES patients.
AIMS: National studies have demonstrated disparities in the treatment and survival of pancreatic cancer patients based on socioeconomic status (SES). This study aimed to identify specific differences in perioperative management and outcomes based on patient SES and to study the role of a multidisciplinary clinic (MDC) in mitigating any variations. METHODS: The study analyzed patients undergoing pancreaticoduodenectomy for pancreatic ductal adenocarcinoma in a large hospital system. The patients were categorized into groups of high and low SES and whether they were managed by the authors' pancreatic cancer MDC or not. The study compared differences in disease characteristics, receipt of multimodality therapy, perioperative outcomes, and recurrence-free and overall survival. RESULTS: Of the 162 low-SES patients and 119 high-SES patients, 54% were managed in the MDC. Outside the MDC, low-SES patients were less likely to receive neoadjuvant chemotherapy and had less minimally invasive surgery, a longer OR time, less enhanced recovery participation, and more major complications (p < 0.05). No SES disparities were observed among the MDC patients. Despite similar tumor characteristics, the low-SES patients had inferior median overall survival (21 vs 32 months; p = 0.005), but the MDC appeared to eliminate this disparity. Low SES correlated with inferior survival for the non-MDC patients (17 vs 32 months; p < 0.001), but not for the MDC patients (24 vs 25 months; p = 0.33). These findings persisted in the multivariable analysis. CONCLUSION: A pancreatic cancer MDC standardizes treatment decisions, eliminates disparities in surgical outcomes, and improves survival for low-SES patients.
Authors: Douglas S Swords; Sean J Mulvihill; Benjamin S Brooke; Matthew A Firpo; Courtney L Scaife Journal: Ann Surg Oncol Date: 2019-10-11 Impact factor: 5.344
Authors: R Cutler Quillin; Gregory C Wilson; Koffi Wima; Samuel F Hohmann; Jeffrey M Sutton; Joshua J Shaw; Ian M Paquette; E Steve Woodle; Daniel E Abbott; Shimul A Shah Journal: Clin Gastroenterol Hepatol Date: 2014-06-04 Impact factor: 11.382
Authors: Caroline Rieser; Heather Phelos; Amer Zureikat; James Pingpank; Melanie Ongchin; Andrew Lee; Joshua Brown; M Haroon Choudry; Richard S Hoehn Journal: Ann Surg Oncol Date: 2022-05-31 Impact factor: 4.339
Authors: Shamir O Cawich; Neil W Pearce; Vijay Naraynsingh; Parul Shukla; Rahul R Deshpande Journal: World J Clin Cases Date: 2022-08-06 Impact factor: 1.534
Authors: Scarlett Hao; Anastasios Mitsakos; William Irish; Janet Elizabeth Tuttle-Newhall; Alexander A Parikh; Rebecca A Snyder Journal: J Surg Oncol Date: 2022-03-22 Impact factor: 2.885